Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL-301 in Advanced Solid Tumors
NCT05181865Phase 2Withdrawn
- Sponsor
- Flame Biosciences
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of NBL-015 in pancreatic cancer (PC), gastric cancer (GC), solid tumor, sponsored by Flame Biosciences. Planned start Jan 2022; status: withdrawn.
02
Drugs
NBL-015
03
Conditions
pancreatic cancer (PC)gastric cancer (GC)solid tumor
Beyond the preview
Go deeper on NCT05181865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181865.